TARRYTOWN, N.Y., Aug. 3, 2021 /PRNewswire/ -- Regeneron
Pharmaceuticals, Inc. (NASDAQ: REGN) today announced winners
of the ninth annual Regeneron Prize for Creative Innovation, a
competition designed to recognize creativity and independent
scientific thinking among postdoctoral fellows and graduate
students focused on biomedical research. Each year, the country's
leading research universities are invited to nominate top
candidates, who then attend a virtual competition to present their
"dream project" proposals for innovations in biomedical research to
a selection committee of Regeneron scientists and leadership.
This year's winners are Sergey D.
Stavisky, Ph.D., of Stanford
University in the postdoctoral fellow category and
Nitsan Goldstein of the
University of Pennsylvania in the
graduate student category. Each winner received $50,000 in prize money, along with a $5,000 donation to their institution, and ten
additional finalists were awarded $5,000 each.
"The world needs bold, curious thinkers like Sergey and Nitsan
to lead the next era of biomedical progress, particularly in
historically challenging fields like neurology, and we are proud to
support their ambitions through the Regeneron Prize for Creative
Innovation," said George D.
Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of
Regeneron. "The COVID-19 pandemic has emphasized the importance of
fostering and investing in early scientific research to enable
future medical breakthroughs, and we are enthused to see brilliant
young people furthering these important efforts."
Dr. Stavisky studies neuroscience and neural engineering and
develops brain-computer interfaces to restore speech and complex
arm movements in Stanford's Neural
Prosthetics Translational Laboratory under advisors Dr.
Jaimie Henderson and Dr.
Krishna Shenoy. He hopes his work
will inform approaches for applying technological innovations to
restore people's ability to communicate and move.
Ms. Goldstein studies neuroscience in the laboratory of Dr.
Nicholas Betley at the University of Pennsylvania. Her work focuses on the
neural control of food intake, specifically investigating how the
gut communicates with hypothalamic neurons to signal satiety,
and how these neurons affect downstream circuits to alter
motivation and reward. Her research has potential applications to
the treatment of obesity and other metabolic disorders.
"For the ninth year running, we continue to see outstanding
dream projects presented by the best and brightest young minds,"
said David Glass, M.D., Vice
President of Research and Chair of the Postdoctoral Program at
Regeneron. "This year's winners and finalists once again
demonstrated the power and innovative spirit of the next generation
of scientists. We are eager to see how they inspire others to
pursue their passion and pave the way for further scientific
advancements."
Requests for applications are distributed to academic
institutions late each fall. Institutions are asked to nominate two
graduate students and two postdoctoral fellows. In addition to the
dream project proposals, submissions must include a curriculum
vitae and samples of publications that enable the selection
committee to review each nominee's scholarly productivity. For more
information, please email science.education@regeneron.com.
About Regeneron Pharmaceuticals, Inc.
Regeneron (NASDAQ: REGN) is a leading biotechnology company
that invents life-transforming medicines for people with serious
diseases. Founded and led for over 30 years by
physician-scientists, our unique ability to repeatedly and
consistently translate science into medicine has led to nine
FDA-approved treatments and numerous product candidates in
development, almost all of which were homegrown in our
laboratories. Our medicines and pipeline are designed to help
patients with eye diseases, allergic and inflammatory diseases,
cancer, cardiovascular and metabolic diseases, pain, hematologic
conditions, infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug
development process through our
proprietary VelociSuite® technologies,
such as VelocImmune®, which uses unique
genetically humanized mice to produce optimized fully human
antibodies and bispecific antibodies, and through ambitious
research initiatives such as the Regeneron Genetics Center, which
is conducting one of the largest genetics sequencing efforts in the
world.
For additional information about the company, please
visit www.regeneron.com or follow @Regeneron on
Twitter.
Regeneron Media Relations
Ella Campbell
Tel: +1
914-572-4003
ella.campbell@regeneron.com
View original
content:https://www.prnewswire.com/news-releases/regeneron-announces-the-2021-winners-of-the-regeneron-prize-for-creative-innovation-301346757.html
SOURCE Regeneron Pharmaceuticals, Inc.